Two-year Efficacy of Entecavir for the Treatment of Chronic Hepatitis B,Compensated and Decompensated Cirrhosis

Objective To compare antiviral effects of entecavir in patients with chronic hepatitis B,compensated and decompensated cirrhosis patients after 2 years of treatment with entecavir.Methods Totally 63 treatment-nave patients with chronic hepatitis B(41 cases),compensated(15 cases) and decompensated cirrhosis(7 cases) patients were treated with entecavir 0.5 mg once daily.Alanine aminotransferase(ALT) and HBV DNA were detected and analyzed at three-month interval.Results The baseline characteristics of the three groups were comparable by age,gender,ALT and HBV DNA.There was no significant difference in ALT normalization and HBeAg seroconversion rate after one-year and two-year entecavir treatment.The 2-year HBV DNA undetectable(5×105 IU/mL) rate and median reductions were 81.8% and 5.4 lg in chronic hepatitis B,83.3% and 6.0 lg in compensated cirrhosis,88.1% and 5.8 lg in decompensated cirrhosis.The kinetics of HBV DNA suppression at every 3 months interval were similar among three groups.Conclusion There was no significant difference efficacy of after 2 years of treatment with entecavir in patients with chronic hepatitis B,compensated and decompensated cirrhosis patients.